Publication:
The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: Modelling mass drug administration and treatment

dc.contributor.authorRichard J. Maudeen_US
dc.contributor.authorChea Nguonen_US
dc.contributor.authorArjen M. Dondorpen_US
dc.contributor.authorLisa J. Whiteen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.contributor.otherNational Centre for Parasitology, Entomology and Malaria Controlen_US
dc.date.accessioned2018-11-09T02:20:47Z
dc.date.available2018-11-09T02:20:47Z
dc.date.issued2014-09-24en_US
dc.description.abstract© 2014Maude et al.; licensee BioMed Central Ltd. Background: Artemisinin resistance is a major threat to current efforts to eliminate Plasmodium falciparum malaria which rely heavily on the continuing efficacy of artemisinin combination therapy (ACT). It has been suggested that ACT should not be used in mass drug administration (MDA) in areas where artemisinin-resistant P. falciparum is prevalent, and that atovaquone-proguanil (A-P) might be a preferable alternative. However, a single point mutation in the cytochrome b gene confers high level resistance to atovaquone, and such mutant parasites arise frequently during treatment making A-P a vulnerable tool for elimination.Methods. A deterministic, population level, mathematical model was developed based on data from Cambodia to explore the possible effects of large-scale use of A-P compared to dihydroartemisinin-piperaquine ACT for mass drug administration and/or treatment of P. falciparum malaria, with and without adjunctive primaquine (PQ) and long-lasting insecticide-treated bed nets (LLIN). The aim was local elimination.Results: The model showed the initial efficacy of ACT and A-P for MDA to be similar. However, each round of A-P MDA resulted in rapid acquisition and spread of atovaquone resistance. Even a single round of MDA could compromise efficacy sufficient to preclude its use for treatment or prophylaxis. A switch to A-P for treatment of symptomatic episodes resulted in a complete loss of efficacy in the population within four to five years of its introduction. The impact of MDA was temporary and a combination of maintained high coverage with ACT treatment for symptomatic individuals and LLIN was necessary for elimination.Conclusion: For malaria elimination, A-P for MDA or treatment of symptomatic cases should be avoided. A combined strategy of high coverage with ACT for treatment of symptomatic episodes, LLIN and ACT + P MDA would be preferable.en_US
dc.identifier.citationMalaria Journal. Vol.13, No.1 (2014)en_US
dc.identifier.doi10.1186/1475-2875-13-380en_US
dc.identifier.issn14752875en_US
dc.identifier.other2-s2.0-84907681239en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/33950
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84907681239&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleThe diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: Modelling mass drug administration and treatmenten_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84907681239&origin=inwarden_US

Files

Collections